nach oben

Erschienen in:

01.09.2011 | Original Article

Identification and characterization of a natural inter-genotypic (2b/1b) recombinant hepatitis C virus in Japan

verfasst von: Koji Yokoyama, Masaharu Takahashi, Tsutomu Nishizawa, Shigeo Nagashima, Suljid Jirintai, Shigeru Yotsumoto, Hiroaki Okamoto, Mariko Y. Momoi

Erschienen in: Archives of Virology | Ausgabe 9/2011

Einloggen, um Zugang zu erhalten

Abstract

A hepatitis C virus (HCV) strain (HC10-0804) recovered from a 12-year-old Japanese female with chronic hepatitis C segregated into discordant genotypes, 2b and 1b, in the 5’UTR/core and NS5B regions, respectively, thus suggesting an inter-genotypic recombination. The HC10-0804 isolate had a genomic length of 9,423 nucleotides (nt), excluding the poly(U) tract at the 3’ terminus, and encoded a single open reading frame (ORF) for a polyprotein of 3,014 amino acids (aa). Based on Simplot and Bootscan analyses, the crossover point from 2b to 1b was estimated at nt 3443/3444 (aa 1034/1035), just after the beginning of the NS3 region. Comparison of the entire genomic sequence showed that the HC10-0804 strain was only 90.2% identical to the previously reported 2b/1b recombinant strain (SE-03-07-1689) from the Philippines, whose putative crossover point was 24 nt downstream of that of HC10-0804. These results indicate the circulation of a novel inter-genotypic (2b/1b) recombinant HCV in Japan.

Chayama K, Tsubota A, Kobayashi M, Okamoto K, Hashimoto M, Miyano Y, Koike H, Koida I, Arase Y, Saitoh S, Suzuki Y, Murashima N, Ikeda K, Kumada H (1997) Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection. Hepatology 25:745–749PubMedCrossRef

Chung H, Ueda T, Kudo M (2010) Changing trends in hepatitis C infection over the past 50 years in Japan. Intervirology 53:39–43PubMedCrossRef

El-Shamy A, Nagano-Fujii M, Sasase N, Imoto S, Kim SR, Hotta H (2008) Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy. Hepatology 48:38–47PubMedCrossRef

Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, Izumi N, Marumo F, Sato C (1996) Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 334:77–81PubMedCrossRef

Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder JC, Strazzera A, Chien DY, Munoz SJ, Balestrieri A, Purcell RH, Alter HJ (2000) The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 288:339–344PubMedCrossRef

Gao F, Nainan OV, Khudyakov Y, Li J, Hong Y, Gonzales AC, Spelbring J, Margolis HS (2007) Recombinant hepatitis C virus in experimentally infected chimpanzees. J Gen Virol 88:143–147PubMedCrossRef

Guillot S, Caro V, Cuervo N, Korotkova E, Combiescu M, Persu A, Aubert-Combiescu A, Delpeyroux F, Crainic R (2000) Natural genetic exchanges between vaccine and wild poliovirus strains in humans. J Virol 74:8434–8443PubMedCrossRef

Holland PV, Barrera JM, Ercilla MG, Yoshida CF, Wang Y, de Olim GA, Betlach B, Kuramoto K, Okamoto H (1996) Genotyping hepatitis C virus isolates from Spain, Brazil, China, and Macau by a simplified PCR method. J Clin Microbiol 34:2372–2378PubMed

Kageyama S, Agdamag DM, Alesna ET, Leaño PS, Heredia AM, Abellanosa-Tac-An IP, Jereza LD, Tanimoto T, Yamamura J, Ichimura H (2006) A natural inter-genotypic (2b/1b) recombinant of hepatitis C virus in the Philippines. J Med Virol 78:1423–1428PubMedCrossRef

10.

Kalinina O, Norder H, Mukomolov S, Magnius LO (2002) A natural intergenotypic recombinant of hepatitis C virus identified in St. Petersburg. J Virol 76:4034–4043PubMedCrossRef

11.

Kalinina O, Norder H, Magnius LO (2004) Full-length open reading frame of a recombinant hepatitis C virus strain from St Petersburg: proposed mechanism for its formation. J Gen Virol 85:1853–1857PubMedCrossRef

12.

Kanai K, Kako M, Okamoto H (1992) HCV genotypes in chronic hepatitis C and response to interferon. Lancet 339:1543PubMedCrossRef

13.

Korenaga M, Hino K, Katoh Y, Yamaguchi Y, Okuda M, Yoshioka K, Okita K (2001) A possible role of hypervariable region 1 quasispecies in escape of hepatitis C virus particles from neutralization. J Viral Hepat 8:331–340PubMedCrossRef

14.

Kurbanov F, Tanaka Y, Chub E, Maruyama I, Azlarova A, Kamitsukasa H, Ohno T, Bonetto S, Moreau I, Fanning LJ, Legrand-Abravanel F, Izopet J, Naoumov N, Shimada T, Netesov S, Mizokami M (2008) Molecular epidemiology and interferon susceptibility of the natural recombinant hepatitis C virus strain RF1_2k/1b. J Infect Dis 198:1448–1456PubMedCrossRef

15.

Lai MM (1992) Genetic recombination in RNA viruses. Curr Top Microbiol Immunol 176:21–32PubMed

16.

Lauer GM, Walker BD (2001) Hepatitis C virus infection. N Engl J Med 345:41–52PubMedCrossRef

17.

Lee YM, Lin HJ, Chen YJ, Lee CM, Wang SF, Chang KY, Chen TL, Liu HF, Chen YM (2010) Molecular epidemiology of HCV genotypes among injection drug users in Taiwan: full-length sequences of two new subtype 6w strains and a recombinant form_2b6w. J Med Virol 82:57–68PubMedCrossRef

18.

Legrand-Abravanel F, Claudinon J, Nicot F, Dubois M, Chapuy-Regaud S, Sandres-Saune K, Pasquier C, Izopet J (2007) New natural intergenotypic (2/5) recombinant of hepatitis C virus. J Virol 81:4357–4362PubMedCrossRef

19.

Lole KS, Bollinger RC, Paranjape RS, Gadkari D, Kulkarni SS, Novak NG, Ingersoll R, Sheppard HW, Ray SC (1999) Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J Virol 73:152–160PubMed

20.

Mohamed MK, Magder LS, Abdel-Hamid M, El-Daly M, Mikhail NN, Abdel-Aziz F, Medhat A, Thiers V, Strickland GT (2006) Transmission of hepatitis C virus between parents and children. Am J Trop Med Hyg 75:16–20PubMed

21.

Moradpour D, Penin F, Rice CM (2007) Replication of hepatitis C virus. Nat Rev Microbiol 5:453–463PubMedCrossRef

22.

Moreau I, Hegarty S, Levis J, Sheehy P, Crosbie O, Kenny-Walsh E, Fanning LJ (2006) Serendipitous identification of natural intergenotypic recombinants of hepatitis C in Ireland. Virol J 3:95PubMedCrossRef

23.

Morel V, Fournier C, Francois C, Brochot E, Helle F, Duverlie G, Castelain S (2011) Genetic recombination of the hepatitis C virus: clinical implications. J Viral Hepat 18:77–83PubMedCrossRef

24.

Nakatani SM, Santos CA, Riediger IN, Krieger MA, Duarte CA, Lacerda MA, Biondo AW, Carrilho FJ, Ono-Nita SK (2010) Development of hepatitis C virus genotyping by real-time PCR based on the NS5B region. PLoS ONE 5:e10150PubMedCrossRef

25.

National Institutes of Health (2002) NIH consensus statement on management of hepatitis C: 2002. NIH Consens State Sci Statements 19:1–46

26.

Noppornpanth S, Lien TX, Poovorawan Y, Smits SL, Osterhaus AD, Haagmans BL (2006) Identification of a naturally occurring recombinant genotype 2/6 hepatitis C virus. J Virol 80:7569–7577PubMedCrossRef

27.

Ohto H, Terazawa S, Sasaki N, Hino K, Ishiwata C, Kako M, Ujiie N, Endo C, Matsui A et al (1994) Transmission of hepatitis C virus from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study Group. N Engl J Med 330:744–750PubMedCrossRef

28.

Okada S, Akahane Y, Suzuki H, Okamoto H, Mishiro S (1992) The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. Hepatology 16:619–624PubMedCrossRef

29.

Okamoto H, Kojima M, Okada S, Yoshizawa H, Iizuka H, Tanaka T, Muchmore EE, Peterson DA, Ito Y, Mishiro S (1992) Genetic drift of hepatitis C virus during an 8.2-year infection in a chimpanzee: variability and stability. Virology 190:894–899PubMedCrossRef

30.

Okamoto H, Kurai K, Okada S, Yamamoto K, Lizuka H, Tanaka T, Fukuda S, Tsuda F, Mishiro S (1992) Full-length sequence of a hepatitis C virus genome having poor homology to reported isolates: comparative study of four distinct genotypes. Virology 188:331–341PubMedCrossRef

31.

Okamoto H, Tokita H, Sakamoto M, Horikita M, Kojima M, Iizuka H, Mishiro S (1993) Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection. J Gen Virol 74(Pt 11):2385–2390PubMedCrossRef

32.

Reiter J, Perez-Vilaro G, Scheller N, Mina LB, Diez J, Meyerhans A (2011) Hepatitis C virus RNA recombination in cell culture. J Hepatol. doi:10.1016/j.jhep.2010.12.038

33.

Santti J, Hyypia T, Kinnunen L, Salminen M (1999) Evidence of recombination among enteroviruses. J Virol 73:8741–8749PubMed

34.

Shepard CW, Finelli L, Alter MJ (2005) Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5:558–567PubMedCrossRef

35.

Simmonds P, Bukh J, Combet C, Deléage G, Enomoto N, Feinstone S, Halfon P, Inchauspé G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky JM, Penin F, Sablon E, Shin-I T, Stuyver LJ, Thiel HJ, Viazov S, Weiner AJ, Widell A (2005) Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42:962–973PubMedCrossRef

36.

Tallo T, Norder H, Tefanova V, Krispin T, Schmidt J, Ilmoja M, Orgulas K, Pruunsild K, Priimägi L, Magnius LO (2007) Genetic characterization of hepatitis C virus strains in Estonia: fluctuations in the predominating subtype with time. J Med Virol 79:374–382PubMedCrossRef

37.

Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S (2011) MEGA5: Molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol (submitted) (Publication PDF at http://www.kumarlab.net/publications)

38.

Tanaka T, Tsukiyama-Kohara K, Yamaguchi K, Yagi S, Tanaka S, Hasegawa A, Ohta Y, Hattori N, Kohara M (1994) Significance of specific antibody assay for genotyping of hepatitis C virus. Hepatology 19:1347–1353PubMedCrossRef

39.

Taniguchi S, Okamoto H, Sakamoto M, Kojima M, Tsuda F, Tanaka T, Munekata E, Muchmore EE, Peterson DA, Mishiro S (1993) A structurally flexible and antigenically variable N-terminal domain of the hepatitis C virus E2/NS1 protein: implication for an escape from antibody. Virology 195:297–301PubMedCrossRef

40.

Trowbridge R, Gowans EJ (1998) Identification of novel sequences at the 5′ terminus of the hepatitis C virus genome. J Viral Hepat 5:95–98PubMedCrossRef

41.

Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Krausslich HG, Mizokami M, Bartenschlager R, Liang TJ (2005) Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11:791–796PubMedCrossRef

42.

Weiner AJ, Brauer MJ, Rosenblatt J, Richman KH, Tung J, Crawford K, Bonino F, Saracco G, Choo QL, Houghton M et al (1991) Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology 180:842–848PubMedCrossRef

43.

Worobey M, Holmes EC (1999) Evolutionary aspects of recombination in RNA viruses. J Gen Virol 80:2535–2543PubMed

44.

Zein NN (2000) Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev 13:223–235PubMedCrossRef

Titel: Identification and characterization of a natural inter-genotypic (2b/1b) recombinant hepatitis C virus in Japan
verfasst von: Koji Yokoyama
Masaharu Takahashi
Tsutomu Nishizawa
Shigeo Nagashima
Suljid Jirintai
Shigeru Yotsumoto
Hiroaki Okamoto
Mariko Y. Momoi
Publikationsdatum: 01.09.2011
Verlag: Springer Vienna
Erschienen in: Archives of Virology / Ausgabe 9/2011
Print ISSN: 0304-8608
Elektronische ISSN: 1432-8798
DOI: https://doi.org/10.1007/s00705-011-1038-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2011

Immunization with dendritic cells transfected in vivo with HIV-1 plasmid DNA induces HIV-1-specific immune responses

Molecular epidemiology of norovirus gastroenteritis in children in Jiangmen, China, 2005–2007

Combinations of a host resistance gene and the CI gene of turnip mosaic virus differentially regulate symptom expression in Brassica rapa cultivars

Genetic analysis of fish iridoviruses isolated in Taiwan during 2001–2009

Sequence analysis of the Lactobacillus temperate phage Sha1